KRT25: A Potential Drug Target for Hair Loss (G147183)

Target Name: KRT25

NCBI ID: G147183

KRT25

KRT25: A Potential Drug Target for Hair Loss

KRT25 (type I inner root sheath specific keratin 25) is a protein that is expressed in the hair matrix, including the terminal 5伪-redoxase gene (TGR5伪) which encodes for the 5伪-redoxase enzyme that is responsible for the production of the 5伪- redoxed hair dye,5伪-HPD. KRT25 is a potential drug target and has been identified as a biomarker for the diagnosis of androgen-dependent hair loss.

KRT25 is a key component of the terminal 谩nagen phase of the hair cycle and is present in the hair matrix at levels of 10-100% throughout the scalp. It is a 16.5 kDa protein that is composed of 11% alpha-helix and 77% 尾-sheet. It has been shown to have a number of unique features that make it an attractive drug target, including:

1. Localized expression in the hair matrix: KRT25 is only expressed in the hair matrix and is not present in the hair fiber or the scalp. This makes it an ideal target for drugs that work by targeting the hair matrix.
2. Potential druggable sites: KRT25 has multiple potential druggable sites, including a N-terminal 伪-helical region, a C-terminal 伪-sheet, and a variable region. These sites make it an attractive target for small molecules and antibodies that can interact with them.
3. Role in hair aging: KRT25 has been shown to be involved in the aging process by regulating the levels of 5伪-redoxase in the hair matrix. It has been shown to be a negative regulator of 5伪-redoxase, which is responsible for the production of the 5伪-redoxed hair dye,5伪-HPD.
4. Potential biomarker for androgen-dependent hair loss: KRT25 has been shown to be expressed in the hair matrix at levels that are affected by androgens, such as testosterone. This makes it an attractive target for drugs that work by targeting androgens.

The 5伪-redoxase enzyme is a key mediator of the androgen-dependent hair loss that occurs in androgen-dependent individuals, such as men and transgender women. The production of 5伪-redoxed hair dye,5伪-HPD, by the 5伪-redoxase enzyme is a well-established cause of androgen-dependent hair loss.

KRT25 has been shown to be involved in the regulation of 5伪-redoxase activity in the hair matrix by binding to its active site and modulating the activity of the enzyme. It has been shown to inhibit the production of 5伪-HPD by the 5伪-redoxase enzyme, while enhancing its own activity.

In addition to its potential role in hair aging and its involvement in the regulation of 5伪-redoxase activity, KRT25 has also been shown to have other unique features that make it an attractive drug target. Its localized expression in the hair matrix, potential druggable sites , and role in androgen-dependent hair loss make it an attractive target for small molecules and antibodies.

Conclusion

KRT25 is a unique protein that has been shown to have a number of unique features that make it an attractive drug target. Its localized expression in the hair matrix, potential druggable sites, and role in androgen-dependent hair loss make it an attractive target for small molecules and antibodies. Further research is needed to fully understand the role of KRT25 in the hair cycle and its potential as a drug target.

Protein Name: Keratin 25

Functions: Essential for the proper assembly of type I and type II keratin protein complexes and formation of keratin intermediate filaments in the inner root sheath (irs) (By similarity). Plays a role in the cytoskeleton organization (PubMed:26902920)

The "KRT25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRT25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets